ArticleCancer immunology, immunotherapy : CII2021
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement.
Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial.Cell reports. Medicine · 2026Trial
- Prognostic significance of integrating pretreatment biopsy-derived Immunoscore and Pan-Immune-Inflammation value in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.Clinical and translational radiation oncology · 2026Article
- Differential infiltration of CD4+ and CD8+ T cells and expression of PD-L1 in paired biopsy and resection specimens of gastric and colorectal adenocarcinomas.Frontiers in oncology · 2026Article
- Comparative Analysis of Tumor-Immune Microenvironment Diversity Among Biopsy, Resection, and Metastatic Colorectal Cancer Specimens.Journal of immunology research · 2026Article
- Mimicking and analyzing the tumor microenvironment.Cell reports methods · 2024Review
- Microenvironment shapes small-cell lung cancer neuroendocrine states and presents therapeutic opportunities.Cell reports. Medicine · 2024Article
- HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?Breast cancer research : BCR · 2024Article
- A biopsy-based Immunoscore in patients with treatment-naïve resectable gastric cancer.Therapeutic advances in medical oncology · 2024Article
- LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.Scientific reports · 2023Article
- Neoadjuvant Immunotherapy for Localized Pancreatic Cancer: Challenges and Early Results.Cancers · 2023Review
- Influences of intratumoral heterogeneity on assessment of tumor microenvironment in esophageal squamous cell carcinoma.Cancer science · 2023Article
- Intratumoral Budding in Pretreatment Biopsies, among Tumor Microenvironmental Components, Can Predict Prognosis and Neoadjuvant Therapy Response in Colorectal Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2022Article
- Article
- Understanding cell-cell communication and signaling in the colorectal cancer microenvironment.Clinical and translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) tumor microenvironment (TME) characteristics, such as tumor infiltrating lymphocyte (TIL) densities and PD-L1 status, are predictive of recurrence, disease-free survival, and overall survival. In many malignancies, TME characteristics are also predictive of response to immunotherapy. As window of opportunity studies using neoadjuvant immunotherapy become more common and treatment guidelines incorporate TME features, accurate assessment of the pre-treatment TME using the biopsy specimen is critical. However, no study has thoroughly evaluated the correlation between the TMEs of the biopsy and resection specimens.
methodsWe conducted a retrospective analysis of patients with stage I-III CRC with matched biopsy and resection specimens. CD3+, CD4+, CD8+, and FoxP3+ lymphocyte populations at the center of tumor (CT) and invasive margin (IM) and tumor PD-L1 status in the biopsy and resection specimens were evaluated. TIL populations were compared using Mann-Whitney U tests or Student's t tests and correlated using Pearson r.
resultsCD3+ and CD4+ densities were significantly higher in the CT of the biopsy relative to the resection specimen Comparing biopsy and resection specimens, no TIL population at either the CT or IM had a correlation coefficient > 0.5. Determining PD-L1 status based on biopsy tissue resulted in a sensitivity of 37.1%, specificity of 81.4%, and accuracy of 61.5%.
conclusionsThese findings demonstrate significant discordance between the TME of the biopsy and resection specimens. Caution should be used when basing treatment decisions on pre-treatment endoscopic biopsy findings and when interpreting changes in the TME between pre-treatment biopsy and resection specimens after neoadjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.